NCT06643728

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 240 (estimated)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Bimagrumab	Administered SC
DRUG	Tirzepatide	Administered SC
DRUG	Bimagrumab Placebo	Administered SC
DRUG	Tirzepatide Placebo	Administered SC

Timeline

• Start date: 2024-10-21
• Primary completion: 2026-04-01
• Completion: 2027-01-01
• First posted: 2024-10-16
• Last updated: 2025-09-26

Locations

12 sites across 1 country: United States

Regulatory

• FDA-regulated drug study